Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >Pharmaceutical intermediates >Heterocyclic compound >Pyridine compound >Bromopyridine >4-BROMO-2-TRIFLUOROMETHYLPYRIDINE

4-BROMO-2-TRIFLUOROMETHYLPYRIDINE

4-BROMO-2-TRIFLUOROMETHYLPYRIDINE Structure
  • ₹0
  • Product name: 4-BROMO-2-TRIFLUOROMETHYLPYRIDINE
  • CAS: 887583-90-6
  • MF: C6H3BrF3N
  • MW: 225.99
  • EINECS:
  • MDL Number:MFCD07774089
  • Synonyms:4-BROMO-2-TRIFLUOROMETHYLPYRIDINE;2-(Trifluoromethyl)-4-bromopyridine;4-Bromo-2-(trifluoromethyl);4-Bromo-alpha,alpha,alpha-trifluoro-2-picoline;EOS-61272;4-Bromo-2-(trifL;Pyridine, 4-bromo-2-(trifluoromethyl)-;4-BROMO-2-TRIFLUOROMETHYLPYRIDINE ISO 9001:2015 REACH
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

Boiling point :167.4±35.0 °C(Predicted)
Density :1.707±0.06 g/cm3(Predicted)
storage temp. :under inert gas (nitrogen or Argon) at 2–8 °C
solubility :Chloroform (Slightly), Ethyl Acetate (Slightly)
form :liquid
pka :-1.23±0.10(Predicted)
color :Colourless

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H315 Causes skin irritation Skin corrosion/irritation Category 2 Warning GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H319 Causes serious eye irritation Serious eye damage/eye irritation Category 2A Warning GHS hazard pictograms P264, P280, P305+P351+P338,P337+P313P
H335 May cause respiratory irritation Specific target organ toxicity, single exposure;Respiratory tract irritation Category 3 Warning GHS hazard pictograms
Precautionary statements:
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves/protective clothing/eye protection/face protection.

Description

4-Bromo-2-(trifluoromethyl)pyridine is used in the synthesis of a potent and selective Class IIa histone deacetylase inhibitors as a potential therapy for Huntington’s disease.

Related product price